Pharmacological Management of Behavioral and Psychiatric Symptoms in Older Adults with Intellectual Disability

详细信息    查看全文

• 作者：Nicole Eady ; Ken Courtenay ; André Strydom
• 刊名：Drugs & Aging
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：32
• 期：2
• 页码：95-102
• 全文大小：256 KB
• 参考文献：1. Maulik P, Mascherenhas MN, Mathers CD, Dua T, Saxena S. Prevalance of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32:419-6. <a class="external" href="http://dx.doi.org/10.1016/j.ridd.2010.12.018" target="_blank" title="It opens in new window">CrossRefa>
  2. Emerson E, Baines S, Allerton L, Welch V. Health inequalities and people with learning disabilities in the UK [Internet]. 2011. <a href="http://www.improvinghealthandlives.org.uk/securefiles/141107_0947//IHaL%202011-09%20HealthInequality2011.pdf" class="a-plus-plus">http://www.improvinghealthandlives.org.uk/securefiles/141107_0947//IHaL%202011-09%20HealthInequality2011.pdfa>. Accessed 1 Nov 2014.
  3. Matthews T, Weston N, Baxter H, Felce D, Kerr M. A general practice-based prevalence study of epilepsy among adults with intellectual disabilities and of its association with psychiatric disorder, behaviour disturbance and carer stress. J Intellect Disabil Res. 2008;52(2):163-3. <a class="external" href="http://dx.doi.org/10.1111/j.1365-2788.2007.01025.x" target="_blank" title="It opens in new window">CrossRefa>
  4. Cooper S-A, Smiley E, Morrison J, Williamson A, Allan L. Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry. 2007;190(1):27-5. <a class="external" href="http://dx.doi.org/10.1192/bjp.bp.106.022483" target="_blank" title="It opens in new window">CrossRefa>
  5. Bittles AH, Petterson BA, Sullivan SG, Hussain R, Glasson EJ, Montgomery PD. The influence of intellectual disability on life expectancy. J Gerontol A Biol Sci Med Sci. 2002;57(7):M470-. <a class="external" href="http://dx.doi.org/10.1093/gerona/57.7.M470" target="_blank" title="It opens in new window">CrossRefa>
  6. Glasson E, Sullivan S, Hussain R, Petterson B, Montgomery P, Bittles A. The changing survival profile of people with Down’s syndrome: implications for genetic counselling. Clin Genet. 2002;62(5):390-. <a class="external" href="http://dx.doi.org/10.1034/j.1399-0004.2002.620506.x" target="_blank" title="It opens in new window">CrossRefa>
  7. Glover G, Ayub M. How people with learning disabilities die. [Internet]. 2010. <a href="http://www.improvinghealthandlives.org.uk/publications/year/2010" class="a-plus-plus">http://www.improvinghealthandlives.org.uk/publications/year/2010a>. Accessed 1 Nov 2014.
  8. Strydom A, Shooshtari S, Lee L, Raykar V, Torr J, Tsiouris J, et al. Dementia in older adults with intellectual disabilities—epidemiology, presentation, and diagnosis. J Policy Pract Intellect Disabil. 2010;7(2):96-10. <a class="external" href="http://dx.doi.org/10.1111/j.1741-1130.2010.00253.x" target="_blank" title="It opens in new window">CrossRefa>
  9. Haveman M, Heller T, Lee L, Maaskant M, Shooshtari S, Strydom A. Major health risks in aging persons with intellectual disabilities: an overview of recent studies. J Policy Pract Intellect Disabil. 2010;7(1):59-9. <a class="external" href="http://dx.doi.org/10.1111/j.1741-1130.2010.00248.x" target="_blank" title="It opens in new window">CrossRefa>
  10. Jansen J, Rozeboom W, Penning C, Evenhuis HM. Prevalence and incidence of myocardial infarction and cerebrovascular accident in ageing persons with intellectual disability. J Intellect Disabil Res. 2013;57(7):681-. <a class="external" href="http://dx.doi.org/10.1111/j.1365-2788.2012.01567.x" target="_blank" title="It opens in new window">CrossRefa>
  11. Haveman M, Perry J, Salvador-Carulla L, Walsh PN, Kerr M, Van Schrojenstein Lantman-de Valk H, et al. Ageing and health status in adults with intellectual disabilities: Results of the European POMONA II study. J Intellect Dev Disabil. 2011;36(1):49-0.
  12. Deb S, Kwok H, Bertelli M, Salvador-Carulla L, Bradley E, Torr J, et al. International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry. 2009;8(3):181-.
  13. Sawyer A, Lake JK, Lunsky Y, Liu S-K, Desarkar P. Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: a systematic review. Res Autism Spectr Disord. 2014;8(7):803-3. <a class="external" href="http://dx.doi.org/10.1016/j.rasd.2014.03.021" target="_blank" title="It opens in new window">CrossRefa>
  14. Strydom A, Livingston G, King M, Hassiotis A. Prevalence of dementia in intellectual disability using different diagnostic criteria. Br J Psychiatry. 2007;191(2):150-. <a class="external" href="http://dx.doi.org/10.1192/bjp.bp.106.028845" target="_blank" title="It opens in new window">CrossRefa>
  15. Strydom A, Hassiotis A, Livingston G. Mental health and social care needs of older people with intellectual disabilities. J Appl Res Intellect Disabil. 2005;18(3):229-5. <a class="external" href="http://dx.doi.org/10.1111/j.1468-3148.2005.00221.x" target="_blank" title="It opens in
• 刊物主题：Geriatrics/Gerontology; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine;
• 出版者：Springer International Publishing
• ISSN：1179-1969

文摘

Given medical and social advances, the life expectancy of individuals with intellectual disability (ID) has increased dramatically, leading to a generation of older individuals with such disabilities. This review focuses on the pharmacological treatment of behavioral and psychiatric symptoms and disorders in older adults with ID. Older adults with ID often present with medical co-morbidities and mental health issues. Medication management of behavioral and psychiatric problems is complicated by a higher risk for adverse events, lack of decision-making capacity, and complex care networks. Some studies have shown that individuals with ID and co-morbid mental disorders are undertreated in comparison with those with similar disorders in the general population, resulting in poorer outcomes. However, older adults with ID are also at risk of polypharmacy, and older age is a risk factor for development of side effects. A general principle is that medication treatment for psychiatric disorders in older individuals with ID should be started at low dosages and increased cautiously while monitoring response and side effects. The use of psychotropic drugs for older individuals with ID and behavioral problems remains controversial, particularly in those with dementia.